Julia Pohl
Overview
Explore the profile of Julia Pohl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pohl J, Totzeck M, Mincu R, Margraf S, Scheipers L, Michel L, et al.
ESC Heart Fail
. 2022 Jul;
9(5):3533-3542.
PMID: 35894541
Aims: While immune checkpoint inhibitor (ICI) therapy significantly improves survival rates in advanced melanoma, ICI can evoke severe immune-related cardiovascular adverse events. Right ventricular (RV) dysfunction negatively impacts the outcomes...
2.
Pohl J, Mincu R, Mrotzek S, Wakili R, Mahabadi A, Potthoff S, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33801913
Objective: To evaluate a new electrocardiographic (ECG) score reflecting domains of electrical and structural alterations in therapy-naïve cancer patients to assess their risk of cardiotoxicity. Methods: We performed a retrospective...
3.
Tagliavini M, Weidler P, Njel C, Pohl J, Richter D, Bohringer B, et al.
Water Res
. 2020 Aug;
185:116249.
PMID: 32777598
The European Union has proposed the value of 1 ng L as a drinking water quality standard for estradiol. With conventional technologies only partially removing estradiol, the investigation of novel...
4.
Pohl J, Mincu R, Mrotzek S, Hinrichs L, Michel L, Livingstone E, et al.
J Clin Med
. 2020 Jul;
9(7).
PMID: 32630003
We aimed to evaluate whether therapy with immune checkpoint inhibitors (ICI) leads to changes in electrocardiogram (ECG) parameters in melanoma patients. We retrospectively examined 41 patients (46% women, age 61...
5.
Hinrichs L, Mrotzek S, Mincu R, Pohl J, Roll A, Michel L, et al.
Front Pharmacol
. 2020 Jun;
11:740.
PMID: 32508657
Background: The long-term survival of cancer patients has significantly improved over the past years. Despite their therapeutic efficacy, various cancer therapies are associated with cardiotoxicity. Therefore, timely detection of cardiotoxic...
6.
Pohl J, Luedike P, Janosi R, Rassaf T
J Heart Valve Dis
. 2018 Sep;
26(6):728-730.
PMID: 30207125
MitraClip® implantation is commonly used in patients with severe mitral regurgitation (MR) and who are at high risk for surgical mitral valve repair. The occurrence of stroke or transient ischemic...
7.
Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N, et al.
Eur J Med Res
. 2018 May;
23(1):22.
PMID: 29728137
Background: Prognostication in heart failure with preserved ejection fraction (HFpEF) is challenging and novel biomarkers are urgently needed. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that plays a...
8.
Luedike P, Alatzides G, Papathanasiou M, Heisler M, Pohl J, Lehmann N, et al.
Cytokine
. 2018 May;
110:104-109.
PMID: 29723777
Background: Heart failure (HF) is characterized by impaired systolic ejection capacity and/or diastolic filling of the heart, leading to a multisystem disorder. Remote organ failure, systemic inflammation or pulmonary hypertension...
9.
Papathanasiou M, Pohl J, Janosi R, Pizanis N, Kamler M, Rassaf T, et al.
Ann Thorac Surg
. 2017 Nov;
105(2):557-563.
PMID: 29174784
Background: Although the effect of infections with multidrug-resistant bacteria (MDRB) in left ventricular assist device (LVAD) recipients is well characterized, the influence of perioperative colonization on the development of infections...
10.
Pohl J, Hendgen-Cotta U, Stock P, Luedike P, Baba H, Kamler M, et al.
J Clin Med
. 2017 Oct;
6(10).
PMID: 29027966
Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory protein and contributes to several different inflammatory and ischemic/hypoxic diseases. MIF was shown to be cardioprotective in experimental myocardial ischemia/reperfusion injury...